SCHEMBL4773622

SCHEMBL4773622

O=S(=O)(CCNc1cc(-c2cccnc2)nc(-c2ccccn2)n1)c1ccccn1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 1/20 0.46
CYP3A4 P08684 3/20 0.45
CYP2C9 P11712 1/20 0.45
SLC2A1 P11166 1/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
PPP1CA P62136 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
NPC1 O15118 2/20 0.43
TP53 P04637 2/20 0.43
RAB9A P51151 2/20 0.43
PKM P14618 1/20 0.43
TSHR P16473 1/20 0.43
PTGDR Q13258 1/20 0.41
CYP1A2 P05177 2/20 0.40
CYP2D6 P10635 2/20 0.40
CLK4 Q9HAZ1 2/20 0.40
ALDH1A1 P00352 2/20 0.40
HSD17B10 Q99714 1/20 0.40
HIF1A Q16665 1/20 0.40
HDAC1 Q13547 4/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2239971 0.89 SMN1; SMN2 (0.53) CYP2A6CYP3A4CYP2C9SLC2A1SMN1; SMN2
SCHEMBL2241291 0.86 KMT2A (0.46) CYP2A6CYP3A4CYP2C9SLC2A1SMN1; SMN2
SCHEMBL11968288 0.83 CLK4 (0.45) CYP2A6CYP3A4CYP2C9SLC2A1SMN1; SMN2
SCHEMBL2238098 0.81 PTGDR (0.53) CYP2A6CYP3A4CYP2C9SLC2A1SMN1; SMN2
SCHEMBL2240945 0.81 GBA1 (0.54) CYP2A6CYP3A4CYP2C9SLC2A1SMN1; SMN2
SCHEMBL4773053 0.81 MTOR (0.44) CYP3A4CYP2C9SMN1; SMN2NPC1TP53
SCHEMBL2237320 0.80 HIF1A (0.47) CYP2A6CYP3A4CYP2C9SLC2A1SMN1; SMN2
SCHEMBL4768768 0.79 PTGDR (0.53) CYP2A6CYP3A4CYP2C9SMN1; SMN2PPP1CA
SCHEMBL4771978 0.79 PTGDR (0.51) CYP3A4CYP2C9SMN1; SMN2PPP1CAL3MBTL1
SCHEMBL4775842 0.79 CYP3A4 (0.60) CYP2A6CYP3A4CYP2C9SLC2A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1878733-A1 Pyrimidine derivatives as ALK-5 inhibitors Novartis AG (CH) 2008-01-16 EP disclosed